https://casinvent.com/ https://casinvent.com/about https://casinvent.com/about/team https://casinvent.com/about/investors https://casinvent.com/science https://casinvent.com/science/publications https://casinvent.com/pipeline https://casinvent.com/news https://casinvent.com/career https://casinvent.com/contact https://casinvent.com/news/news-36-leadership-transition-at-casinvent https://casinvent.com/news/news-35-czechinvest-grant-successfully-completed-key-milestones-reached-in-ck1-inhibitor-research https://casinvent.com/news/news-34-casinvent-was-selected-for-eic-pre-accelerator-funding-a-crucial-step-in-securing-progress-towards-the-clinic https://casinvent.com/news/news-32-casinvent-participates-in-leukemia360-to-advance-collaboration-in-aml-research https://casinvent.com/news/news-31-casinvent-at-bio-europe-2025-strengthening-global-partnerships https://casinvent.com/news/news-30-casinvent-pharma-at-prague-bio-2025-a-look-back https://casinvent.com/news/news-29-casinvent-reaches-over-25-million-viewers-on-world-cancer-research-day-2025 https://casinvent.com/news/news-28-visit-from-liberi-group-at-casinvent https://casinvent.com/news/news-27-casinvent-was-supported-by-czechinvest-s-technological-incubation-program https://casinvent.com/news/news-26-casinvent-pharma-secures-next-investment-round-with-strong-support-from-existing-and-local-investors-to-advance-ck1-inhibitor-development-for-treatment-resistant-cancer-patients https://casinvent.com/news/news-24-casinvent-wins-the-9th-tacr-sigma-public-competition https://casinvent.com/news/news-23-casinvent-pharma-receives-top-honor-at-transfera-technology-days-2024 https://casinvent.com/news/news-22-casinvent-pharma-joins-czech-presidential-delegation-at-the-pharmaceutical-and-biotechnological-forum-in-switzerland https://casinvent.com/news/news-21-panc-cki-consortium-led-by-casinvent-pharma-secures-4m-eurostars-grant-for-pancreatic-cancer-research https://casinvent.com/news/news-20-dr-jean-pierre-bizzari-joining-casinvent-as-a-new-scientific-advisory-board-member https://casinvent.com/news/news-19-casinvent-pharma-raises-1-6-million-in-pre-series-a-financing-to-support-the-development-of-ck1-inhibitors-for-treatment-resistant-solid-and-hematological-tumours https://casinvent.com/news/news-17-sgc-recommends-mu1742-as-a-new-chemical-probe-for-protein-kinases-ck1-and-ck1 https://casinvent.com/news/news-15-casinvent-pharma-raises-1-3-million-from-khan-i-and-i-i-biotech-fund-to-support-the-development-of-new-casein-kinase-1-inhibitors-for-the-treatment-of-leukemias-and-solid-tumors https://casinvent.com/news/news-13-casinvent-pharma-appoints-alexander-scheer-as-cheif-scientific-officer https://casinvent.com/news/news-12-czech-national-institute-for-drug-control-agrees-to-support-casinvent-pharma-during-the-execution-of-preclinical-program https://casinvent.com/news/news-11-casinvent-pharma-receives-the-neuron-award-for-excellent-technology-transfer https://casinvent.com/about/investors/investment-opportunity https://casinvent.com/about/team/leadership-archive